Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1983 1
1985 1
1987 1
1989 1
1990 3
1991 7
1992 13
1993 10
1994 18
1995 17
1996 22
1997 14
1998 19
1999 20
2000 26
2001 19
2002 14
2003 16
2004 11
2005 10
2006 16
2007 12
2008 10
2009 9
2010 10
2011 7
2012 8
2013 10
2014 15
2015 23
2016 27
2017 29
2018 23
2019 21
2020 19
2021 21
2022 21
2023 18
2024 34
2025 71
2026 52

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

650 results

Results by year

Filters applied: . Clear all
Page 1
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.
Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Reyes-Soffer G, et al. Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e48-e60. doi: 10.1161/ATV.0000000000000147. Epub 2021 Oct 14. Arterioscler Thromb Vasc Biol. 2022. PMID: 34647487 Free PMC article. Review.
High levels of lipoprotein(a) [Lp(a)], an apoB100-containing lipoprotein, are an independent and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms associated with increased atherogenesis, inflammation, and thrombosis. ...Despite its d …
High levels of lipoprotein(a) [Lp(a)], an apoB100-containing lipoprotein, are an independent and causal risk factor for athero …
Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a).
Cho L, Nicholls SJ, Nordestgaard BG, Landmesser U, Tsimikas S, Blaha MJ, Leitersdorf E, Lincoff AM, Lesogor A, Manning B, Kozlovski P, Cao H, Wang J, Nissen SE. Cho L, et al. Am Heart J. 2025 Sep;287:1-9. doi: 10.1016/j.ahj.2025.03.019. Epub 2025 Apr 2. Am Heart J. 2025. PMID: 40185318 Free article.
BACKGROUND: Lipoprotein(a), abbreviated Lp(a), consists of apolipoprotein B-100 covalently bound to apolipoprotein(a), and represents an independent, genetically-determined, causal risk factor for atherosclerotic cardiovascular disease (CVD) and calcific aortic sten …
BACKGROUND: Lipoprotein(a), abbreviated Lp(a), consists of apolipoprotein B-100 covalently bound to apolipoprotein(a), and rep …
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, Blankstein R, Brewer LC, Cho L, de Ferranti SD, Gianos E, Gluckman TJ, Gradney KF, Isiadinso I, Lloyd-Jones DM, Marrs JC, Martin SS, McLain KH, Mehta LS, Mora S, Mulugeta WM, Natarajan P, Navar AM, Orringer CE, Polonsky TS, Reynolds HR, Saseen JJ, Shapiro MD, Soffer DE, Tynes SA, Villavaso CD, Virani SS, Wilkins JT. Blumenthal RS, et al. J Am Coll Cardiol. 2026 May 19;87(19):2624-2757. doi: 10.1016/j.jacc.2025.11.016. Epub 2026 Mar 13. J Am Coll Cardiol. 2026. PMID: 41824590 Free article.
STRUCTURE: The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a)....
STRUCTURE: The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslip …
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Writing Committee Members; Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, Blankstein R, Brewer LC, Cho L, de Ferranti SD, Gianos E, Gluckman TJ, Gradney KF, Isiadinso I, Lloyd-Jones DM, Marrs JC, Martin SS, McLain KH, Mehta LS, Mora S, Mulugeta WM, Natarajan P, Navar AM, Orringer CE, Polonsky TS, Reynolds HR, Saseen JJ, Shapiro MD, Soffer DE, Tynes SA, Villavaso CD, Virani SS, Wilkins JT. Writing Committee Members, et al. Circulation. 2026 Apr 28;153(17):e1154-e1276. doi: 10.1161/CIR.0000000000001423. Epub 2026 Mar 13. Circulation. 2026. PMID: 41824552 Free article. Review.
STRUCTURE: The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a)....
STRUCTURE: The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslip …
Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events.
Markus MRP, Ittermann T, Mariño Coronado J, Schipf S, Bahls M, Könemann S, Chamling B, Völzke H, Damasceno NRT, Santos RD, Felix SB, Templin C, Steinhagen-Thiessen E, Dörr M. Markus MRP, et al. Eur Heart J. 2025 Oct 14;46(39):3863-3874. doi: 10.1093/eurheartj/ehaf281. Eur Heart J. 2025. PMID: 40320753 Free PMC article.
Longitudinal associations of low-density lipoprotein cholesterol (LDL-C), lipoprotein(a) [Lp(a)], and high-sensitivity C-reactive protein (Hs-CRP), both individually and in combination, were analysed with the risk for incident MACEs using Cox regression models, stra …
Longitudinal associations of low-density lipoprotein cholesterol (LDL-C), lipoprotein(a) [Lp(a)], and high-sensitivity C-react …
Harmonization of Lipoprotein(a) Immunoassays Using A Serum Panel Value Assigned with The IFCC-Endorsed Mass Spectrometry-Based Reference Measurement Procedure as A First Step Towards Apolipoprotein Standardization.
Miida T, Hirayama S, Fukushima Y, Hori A, Ito S, Hinata M, Wakita M, Tabata H, Tamura Y, Watada H, Kawamori R, Vesper HW, Cobbaert CM. Miida T, et al. J Atheroscler Thromb. 2025 May 1;32(5):580-595. doi: 10.5551/jat.65238. Epub 2024 Nov 6. J Atheroscler Thromb. 2025. PMID: 39505497 Free PMC article.
AIM: Lipoprotein (a) [Lp(a)] is a well-established risk factor for cardiovascular disease independent of low-density lipoprotein-cholesterol (LDL-C). ...Of the five immunoassays, only the Roche Lp(a) assay was traceable to the WHO-IFCC reference materi …
AIM: Lipoprotein (a) [Lp(a)] is a well-established risk factor for cardiovascular disease independent of low-density lipoprote …
Lipoprotein(a) and atherosclerosis.
Scanu AM, Lawn RM, Berg K. Scanu AM, et al. Ann Intern Med. 1991 Aug 1;115(3):209-18. doi: 10.7326/0003-4819-115-3-209. Ann Intern Med. 1991. PMID: 1829339 Free article. Review.
Lipoprotein(a) [Lp(a)], a lipoprotein variant, was relegated for almost 25 years to the study of a few specialists. ...Unfortunately, the available techniques need to be standardized. Apolipoprotein(a) exists in isoforms of different sizes, and …
Lipoprotein(a) [Lp(a)], a lipoprotein variant, was relegated for almost 25 years to the study of a few specialis …
On the cusp of global lipoprotein(a) standardization.
Cobbaert CM, van Neer NJM, Diederiks NM, Leijnse EJJ, Ruhaak LR. Cobbaert CM, et al. Clin Chem Lab Med. 2026 Feb 16;64(5):1064-1073. doi: 10.1515/cclm-2026-0149. Print 2026 Apr 24. Clin Chem Lab Med. 2026. PMID: 41696970 Free article. Review.
Lipoprotein(a) (Lp(a)) has the reputation of being the most misunderstood metric in laboratory medicine. ...Global Lp(a) standardization was first attempted in the nineties by an IFCC Working Group on Lp(a) Standardization using an ELISA-based refer …
Lipoprotein(a) (Lp(a)) has the reputation of being the most misunderstood metric in laboratory medicine. ...Global Lp(a) st …
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.
Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, Francis GA, Genest J, Grégoire J, Grover SA, Gupta M, Hegele RA, Lau D, Leiter LA, Leung AA, Lonn E, Mancini GBJ, Manjoo P, McPherson R, Ngui D, Piché ME, Poirier P, Sievenpiper J, Stone J, Ward R, Wray W. Pearson GJ, et al. Can J Cardiol. 2021 Aug;37(8):1129-1150. doi: 10.1016/j.cjca.2021.03.016. Epub 2021 Mar 26. Can J Cardiol. 2021. PMID: 33781847
For all other patients, we emphasize risk assessment linked to lipid/lipoprotein evaluation to optimize clinical decision-making. Lipoprotein(a) measurement is now recommended once in a patient's lifetime, as part of initial lipid screening to assess cardiovascular …
For all other patients, we emphasize risk assessment linked to lipid/lipoprotein evaluation to optimize clinical decision-making. Lipopro …
Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank.
Bhatia HS, McParland J, Rikhi R, Tsai M, Szklo M, Tsimikas S, Yeang C, Shapiro MD. Bhatia HS, et al. J Am Coll Cardiol. 2025 Nov 25;86(21):2000-2013. doi: 10.1016/j.jacc.2025.08.101. Epub 2025 Nov 10. J Am Coll Cardiol. 2025. PMID: 41217319 Free PMC article.
BACKGROUND: Elevated lipoprotein(a) [Lp(a)] is associated with atherosclerotic cardiovascular disease (ASCVD) risk, and vascular inflammation is one mechanism through which Lp(a) causes ASCVD. ...HRs were presented per standard deviation. Participants were al …
BACKGROUND: Elevated lipoprotein(a) [Lp(a)] is associated with atherosclerotic cardiovascular disease (ASCVD) risk, and vascul …
650 results